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Olefin-Bond Chemodifferentiation through Cross-Metathesis
Reactions: A Stereocontrolled Approach to Functionalized
2,3-Amino Acid Derivatives
Márton Kardos,[a] Loránd Kiss,*[a] Matti Haukka,[b] Santos Fustero,[c] and Ferenc Fülöp*[a,d]
Abstract: Substituted cyclopentanes or tetrahydrofurans bear-
ing two vinyl groups have been investigated in cross-metathesis
reactions to explore chemodiscrimination of the two olefin
bonds. The syntheses consisted of ring opening of constrained
Introduction
In the last two decades, olefin metathesis reactions have revolu-
tionized organic synthesis. This has been made possible by the
development and commercial availability of catalysts with high
activities and remarkable functional-group tolerance.[1] Using
this process, many natural products and biologically active
compounds have been synthesized that were previously un-
available or hard to prepare by any other means.[2]
Olefin metathesis can be carried out in a chemoselective
manner in several ways. The outcome of the reaction is often
catalyst-dependent.[3] Steric or electronic deactivation of one
of the C–C double bonds can also induce chemoselectivity.[4]
Furthermore, several studies reported plausible hydrogen-
bonding interactions in the preassembly phase between the
chloride ligand of the catalyst and a hydrogen atom of the sub-
strate; this would then favour the selective transformation of a
particular C–C double bond.[5]
Although they are less abundant than their α-analogues,
conformationally constrained -amino acids have received
enormous attention in the last 20 years as a consequence of
their high biological relevance. These compounds not only oc-
cur in nature either as small molecular entities or as part of
more complex molecules, but also function as precursors of
-lactams. Moreover, certain carbocyclic -amino acids such as
[a] Institute of Pharmaceutical Chemistry, University of Szeged,
Eötvös u. 6, 6720 Szeged, Hungary
E-mail: kiss.lorand@pharm.u-szeged.hu
fulop@pharm.u-szeged.hu
http://www2.pharm.u-szeged.hu/gyki/uj
[b] Department of Chemistry, University of Jyväskylä,
40014 Jyväskylä, Finland
[c] Departamento de Química Orgánica, Facultad de Farmàcia,
Universidad de Valencia,
Av. Vicente Andrés Estellés, s/n, 46100 Valencia, Spain
[d] MTA-SZTE Stereochemistry Research Group,
Hungarian Academy of Sciences,
Eötvös u. 6, 6720 Szeged, Hungary
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/ejoc.201700064.
Eur. J. Org. Chem. 2017, 1894–1901 © 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim1894
unsaturated -lactams or bicyclic -amino acids, followed by
cross-metathesis to test the chemodifferentiation of the divinyl-
substituted azetidinones or -amino esters in the presence of
various ruthenium-based catalysts.
the five-membered carbocyclic cispentacin (isolated from the
culture broth of a Bacillus cereus) or icofungipen have antifungal
activities.[6] Since the new-generation peptides constructed
from -amino acids are stable to metabolism, proteases, and
peptidases, they are regarded as important biomolecules for
medicinal chemistry.[7] Furthermore, -lactams have attracted
widespread attention over the last 70 years because of their
high antibiotic activity. Despite the spread of resistance, com-
pounds with a 2-azetidinone framework are still among the
most commonly used antibiotics.[8] In addition to their anti-
biotic properties, the -lactam framework has been extensively
used as a versatile synthon to access a wide variety of organic
molecules.[9]
Results and Discussion
In this paper, we present our findings on the olefin-bond che-
modifferentiation in cross-metathesis reactions (CM) of some
divinylated -amino acid derivatives and divinylated -lactams,
which leads to the formation of monocoupled products in a
chemoselective manner.
Recently, we reported the synthesis of new difunctionalized
azetidin-2-ones and -amino acid derivatives through stereo-
controlled ring-opening metathesis (ROM) reactions with ethyl-
ene, induced by available Ru-based catalysts. After the ROM
reaction, the newly formed olefin bonds were further function-
alized through CM reactions with α,-unsaturated ketones or
α,-unsaturated esters.[10] During our recent experimental in-
vestigation, we realized that under appropriately chosen reac-
tion conditions, chemodiscrimination of the olefinic bonds in
CM reactions is achievable. For this reason, we selected diolefin-
ated cyclic derivatives fused with a -lactam skeleton or cyclic
frameworks containing two different functional groups. The
model compounds are esters and protected amino (-amino
acid) derivatives. The aim of this study was to construct mono-
coupled -lactams and cyclic -amino acid derivatives, and to
investigate the chemical behaviour of the C=C bonds involved
in these transformations.
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We started our experiments by investigating the CM reaction
of divinyl-substituted azetidinone (±)-2, derived from lactam
(±)-1.[10b] Lactam (±)-2 was subjected to a CM reaction with
methyl vinyl ketone or acrylic esters in the presence of commer-
cially available Grubbs 1st generation, Grubbs 2nd generation,
Hoveyda–Grubbs 1st generation, and Hoveyda–Grubbs 2nd
generation catalysts. Cross-metathesis products were detected
only in the presence of the Hoveyda–Grubbs 2nd generation
catalyst (HG-2).
Through varying the amount of catalyst (e.g., 1 or 2 mol-%),
temperature (room temperature or reflux), and reaction time
(e.g., 2, 4, or 12 h), we found that the best selectivity was ob-
tained by using 5 mol-% HG-2 catalyst in dry CH2Cl2 for 4 h.
Under these conditions, monometathesized products (±)-3 or
(±)-4 were isolated in moderate yields. In the products, the
α,-unsaturated carbonyl or ester moiety is located near to the
amide nitrogen atom (Scheme 1). Unfortunately, our attempts
to increase the yields of the monocoupled products by varia-
tion of the experimental conditions failed as a result of various
side reactions (polymerization, formation of dicoupled prod-
ucts).
We assume that stereochemical factors (chelate-ring stabil-
ity), hydrogen-bonding ability, and the distance between the
NH group and the C=C bond might be responsible for the ob-
served selectivity in the CM reaction. All of these factors may
affect the outcome of the reaction to some extent. In particular,
although it is less known in metal-catalysed processes,[5] we
suppose that a hydrogen-bonding interaction between the
chlorine atom of the catalyst and the amide N–H moiety as a
hydrogen-bond donor group could direct the olefin bond closer
to the amide nitrogen atom to participate in the coupling reac-
tion (Figure 1). This leads to the monocoupled product before
further coupling can occur.
Monocoupled -lactams (±)-3a and (±)-3b are valuable pre-
cursors for the synthesis of functionalized cispentacins through
opening of the lactam ring. Thus, monocoupled cispentacin
hydrochlorides (±)-5a and (±)-5b were synthesized from the
corresponding -lactams (±)-3a and (±)-3b by ethanolysis [in
the case of (±)-3a, transesterification did not occur]. Next, the
Scheme 1.
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Figure 1. Hydrogen-bonding interaction between the chlorine atom of the
catalyst and the amide N–H moiety.
products were subjected to benzoylation to give new mono-
coupled -amino acid derivatives (±)-6a and (±)-6b (Scheme 1).
Expanding our investigation of olefin-bond chemodifferenti-
ation through cross-metathesis, cyclic -amino acids containing
a five-membered ring were next used as model starting com-
pounds. Divinyl-substituted cispentacin (±)-8, prepared by our
recently published ROM method,[10a] was submitted to the CM
reaction. In contrast to lactam (±)-2, the cross-metathesis reac-
tion of compound (±)-8 with the α,-unsaturated carbonyl com-
pound and esters to give monocoupled products was not
100 % selective. As determined by 1H NMR spectroscopic analy-
sis, a mixture of the two regioisomers (±)-6 and (±)-9 was
formed in a 4:1 ratio as a result of a partial hydrogen-bonding
directing effect (Scheme 2). The major product (±)-6 was iso-
lated by crystallization from hexane/EtOAc, and its NMR spec-
troscopic data were identical with those of the final product
presented in Scheme 1. Unfortunately, the minor product (±)-9
could not be isolated in pure form either by crystallization or
chromatography. Further experiments with variation of the cat-
alyst quantity or using portionwise addition did not give better
results: the dicoupled derivative and/or a polymeric material
was formed.
We were interested in investigating the hydrogen-bonding
directing effect by carrying out experiments using a starting
material that cannot function as a hydrogen-bond donor. To test
our hypothesis, N-Boc-protected (Boc = tert-butoxycarbonyl)
-lactam (±)-10,[11] which cannot act as a hydrogen-bond
donor, was subjected to CM with ethyl acrylate in the presence
of the HG-2 catalyst.
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Scheme 2.
In this case, as expected, when the directing effect was ex-
cluded, the coupling reaction led to a mixture of the two mono-
metathesized isomers (±)-12 and (±)-13 in nearly 2:1 ratio, as
determined by NMR spectroscopic analysis of the crude mixture
(Scheme 3). Our efforts to separate and isolate these two iso-
mers failed. Nevertheless, the NMR spectra clearly indicated
that (±)-12 and (±)-13 were the only products present in the
mixture.
Scheme 3.
Scheme 4.
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The synthetic route developed for the preparation of mono-
coupled -amino acid derivatives could be extended to the syn-
thesis of divinylated transpentacins.
For this purpose, diolefinated amino ester (±)-15 [derived
from (±)-14 by ROM],[10a] where the protected amino group and
the ester group are in a trans relationship, was subjected to
cross-metathesis carried out at room temperature in dry CH2Cl2
with methyl vinyl ketone and acrylic esters in the presence of
the HG-2 catalyst. In contrast with divinyl-cispentacin (±)-8, the
single monocoupled isomers (±)-16a, (±)-16b, and (±)-17 were
formed (Scheme 4). The structure of (±)-16a was also confirmed
by X-ray crystallography (Figure 2).
Since hydrogen-bond-acceptor solvents can disrupt the
hydrogen-bonding interaction between the catalyst and the
substrate, we planned to investigate the effect of solvents on
the CM reaction. The reaction of compound (±)-15 with methyl
acrylate (which in CH2Cl2 selectively gave a single regioisomer)
was carried out in three additional solvents. The results show
that solvents that can participate in hydrogen bonding with the
substrate (dioxane, THF), compete with the catalyst, resulting
in the formation of a mixture of products (±)-16a and (±)-18
(approximately 2:1 ratio, as detected by NMR spectroscopic
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Figure 2. X-ray structure of compound (±)-16a.
analysis of the crude reaction mixture). In contrast, solvents that
cannot form a hydrogen bond (CH2Cl2, PhMe) clearly gave only
a single regioisomer (Schemes 4 and 5).
Interestingly, when another transpentacin stereoisomer,
namely (±)-20 [derived from amino ester (±)-19],[10a] was sub-
jected to the CM reaction with either methyl vinyl ketone or
acrylic esters, an inseparable mixture of regioisomers (±)-21/
(±)-22 or (±)-23/(±)-24, respectively, was formed, each in a
nearly 2:1 ratio (Scheme 6).
Scheme 5.
Scheme 6.
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These results suggest that in addition to the hydrogen-bond-
ing effect, another factor also influences the outcome of the
coupling reactions. The chemoselectivity may originate from
steric effects. It is also highly probable that coordination of the
ruthenium atom to the carbonyl oxygen atom, which creates a
stable six-membered chelate ring, stabilizes the metallacyclo-
butane and hinders further transformations. For T2 and T3,
structures in which the vinyl side-chain and the ester group are
trans to each other, formation of the chelate ring is less favour-
able, and so the cross-metathesis reaction is not selective (Fig-
ure 3).
Figure 3. Structures of metallacyclobutane intermediates.
Since oxygen-containing heterocyclic -amino acids (e.g.,
oxetin)[6a] play an important role in medicinal chemistry, we
extended the CM-based chemoselective functionalization ap-
proach to the preparation of substituted oxygen heterocycles.
Thus, divinylated amino ester (±)-26 [derived from (±)-25
through ROM],[10a] in which the ester and amide groups have
a cis relationship, was treated with ethyl acrylate to give an
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inseparable mixture of the two regioisomers (±)-27 and (±)-28
in a nearly 2:1 ratio (Scheme 7).
Scheme 7.
Next, it seemed logical to evaluate the behaviour of com-
pound (±)-30, the trans counterpart of (±)-26. For this reason,
compound (±)-29, obtained by isomerization of (±)-25 through
its active hydrogen atom, was transformed by ROM into divinyl-
ated derivative (±)-30.[10a] Reaction of the latter with ethyl acryl-
ate in the presence of HG-2 led, analogously to divinylated trans
amino ester (±)-15, to monocoupled derivative (±)-31 as the
sole product (Scheme 8).
Scheme 8.
Conclusions
Transformations involving the chemodifferentiation of various
divinylated functionalized cyclopentanes and bicyclic azetidin-
ones were investigated under cross-metathesis reaction condi-
tions. Depending on their structure, the CM reaction of diolefin-
ated -amino acids or -lactams selectively gave valuable func-
tionalized olefinated derivatives. A hydrogen-bonding directing
effect and stereochemical factors involving chelate-ring forma-
tion proved to be responsible for the chemodiscrimination;
these factors were also supported by NH–NBoc exchange and
solvent effects. The functionalized products synthesized might
be interesting scaffolds for peptides or for medicinal chemistry,
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and may serve as interesting building blocks in organic synthe-
sis.
Experimental Section
General Procedure for the Cross-Metathesis: -Lactam (±)-2, (±)-
11 or -amino ester (±)-8, (±)-15, (±)-20, (±)-26, (±)-30 (100 mg)
was dissolved in anhydrous solvent (20 mL), and catalyst (5 mol-%;
see Schemes) and methyl vinyl ketone, methyl acrylate, or ethyl
acrylate (5 equiv.) were added. The mixture was stirred for the time
and temperature indicated. When TLC indicated that the reaction
was complete, the mixture was concentrated under reduced pres-
sure, and the residue was purified by column chromatography on
silica gel (n-hexane/EtOAc).
General Procedure for the Ring-Opening Metathesis: -Lactam
(±)-1, (±)-10 (100 mg) or -amino ester (±)-7, (±)-14, (±)-19, (±)-25
(100 mg) was dissolved in anhydrous CH2Cl2 (20 mL), and catalyst
(5 mol-%) was added. The mixture was stirred at 20 °C under ethyl-
ene for the time indicated (monitored by TLC). When the reaction
was complete, the mixture was concentrated under reduced pres-
sure, and the residue was purified by column chromatography on
silica gel (n-hexane/EtOAc).
General Procedure for the Preparation of Amino Ester Hydro-
chlorides: -Lactam (±)-3a or (±)-3b (100 mg) was dissolved in
EtOH (2 mL), and HCl solution (30 % in EtOH; 5 mL) was added
dropwise at 0 °C. The reaction mixture was stirred for 5 min, then
it was warmed to room temperature; stirring was continued for 3 h.
When TLC indicated that the reaction was complete, the mixture
was concentrated under reduced pressure, and the residue was pu-
rified by washing with Et2O.
General Procedure for the Preparation of N-Benzoyl-Protected
Amino Esters: Amino ester hydrochloride (±)-5a or (±)-5b
(1.4 mmol) was dissolved in toluene (30 mL). A solution of NaHCO3
(1.1 g) in H2O (20 mL) was added at 0 °C, followed by the dropwise
addition of benzoyl chloride (1 equiv.). The reaction mixture was
stirred at 0 °C for 1 h, then it was diluted with EtOAc (70 mL), and
the mixture was washed with H2O (3 × 50 mL). The organic layer
was dried (Na2SO4) and concentrated under reduced pressure. The
crude material was crystallized from n-hexane/Et2O to give the N-
benzoylamino ester.
General Procedure for the Isomerization Reaction: NaOEt
(1.5 equiv.) was added to a solution of cis-N-protected amino ester
(±)-25 (3.5 mmol) in EtOH (30 mL) at 0 °C, and the mixture was
stirred at 20 °C for 14 h. Then H2O (70 mL) was added, and the
mixture was extracted with CH2Cl2 (3 × 30 mL). The organic layer
was dried with Na2SO4, and concentrated under reduced pressure.
The crude material was purified by column chromatography on sil-
ica gel (n-hexane/EtOAc, 4:1) to give the trans isomer.
Methyl (E)-3-[(1R*,2R*,4S*,5S*)-7-Oxo-2-vinyl-6-azabicyclo-
[3.2.0]heptan-4-yl]acrylate [(±)-3a]
Brown oil (69 mg, 51 %). Rf = 0.44 (n-hexane/EtOAc, 1:3). 1H NMR
(400 MHz, CDCl3): δ = 1.94 (d, J = 14.0 Hz, 1 H, 3-H), 2.48–2.59 (m,
1 H, 3-H), 2.89 (t, J = 8.0 Hz, 1 H, 4-H), 3.02–3.12 (m, 1 H, 2-H), 3.64
(s, 1 H, 1-H), 3.73 (s, 3 H, OCH3), 4.06 (d, J = 4.0 Hz, 1 H, 5-H), 4.97–
5.12 (m, 2 H, =CH), 5.67–5.89 (m, 2 H, =CH), 6.32 (br. s, 1 H, NH),
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6.78–6.94 (m, 1 H, =CH) ppm. 13C NMR (100 MHz, CDCl3): δ = 37.1,
41.3, 45.0, 52.1, 59.2, 61.6, 115.2, 121.9, 141, 149.8, 167.0, 170.2 ppm.
MS (ESI): m/z = 222.25 [M + H]+. C12H15NO3 (221.26): calcd. C 65.14,
H 6.83, N 6.33; found C 64.85, H 6.66, N 6.52.
Ethyl (E)-3-[(1R*,2R*,4S*,5S*)-7-Oxo-2-vinyl-6-azabicyclo[3.2.0]-
heptan-4-yl]acrylate [(±)-3b]
Brown oil (59 mg, 41 %). Rf = 0.46 (n-hexane/EtOAc, 1:3). 1H NMR
(400 MHz, CDCl3): δ = 1.28 (t, J = 8.0 Hz, 3 H, CH3), 1.94 (d, J =
8.0 Hz, 1 H, 3-H), 2.45–2.60 (m, 1 H, 3-H), 2.83–2.94 (m, 1 H, 4-H),
3.02–3.11 (m, 1 H, 2-H), 3.63 (s, 1 H, 1-H), 4.03–4.10 (m, 1 H, 5-H),
4.12–4.24 (m, 2 H, OCH2), 4.95–5.13 (m, 2 H, =CH), 5.65–5.89 (m, 2
H, =CH), 6.29 (br. s, 1 H, NH), 6.78–6.94 (m, 1 H, =CH) ppm. 13C NMR
(100 MHz, CDCl3): δ = 14.6, 37.0, 41.4, 45.2, 59.2, 60.8, 61.7, 115.1,
122.3, 140.9, 149.3, 166.6, 170.1 ppm. MS (ESI): m/z = 236.34 [M +
H]+. C13H17NO3 (235.28): calcd. C 66.36, H 7.28, N 5.95; found C
66.13, H 7.02, N 5.77.
(1R*,2R*,4S*,5S*)-4-[(E)-3-Oxobut-1-en-1-yl]-2-vinyl-6-azabicy-
clo[3.2.0]heptan-7-one [(±)-4]
Brown oil (67 mg, 53 %). Rf = 0.61 (n-hexane/acetone, 1:1). 1H NMR
(400 MHz, CDCl3): δ = 1.95 (d, J = 16.0 Hz, 1 H, 3-H), 2.21 (s, 3 H,
CH3), 2.49–2.60 (m, 1 H, 3-H), 2.91 (t, J = 8.00 Hz, 1 H, 4-H), 3.03–
3.11 (m, 1 H, 2-H), 3.67 (s, 1 H, 1-H), 4.07 (d, J = 4.00 Hz, 1 H, 5-H),
5.00–5.11 (m, 2 H, =CH), 5.70–5.83 (m, 1 H, =CH), 6.02–6.11 (m, 1
H, =CH), 6.54 (br. s, 1 H, NH), 6.64–6.74 (m, 1 H, =CH) ppm. 13C NMR
(100 MHz, CDCl3): δ = 27.3, 37.1, 41.1, 45.1, 59.2, 61.3, 115.0, 131.5,
141.3, 148.7, 170.2, 198.6 ppm. MS (ESI): m/z = 206.11 [M + H]+.
C12H15NO2 (205.26): calcd. C 70.22, H 7.37, N 6.82; found C 70.03, H
7.14, N 6.63.
tert-Butyl (1R*,2R*,4S*,5S*)-7-Oxo-2,4-divinyl-6-azabicy-
clo[3.2.0]heptane-6-carboxylate [(±)-11]
Brown oil (71 mg, 63 %). Rf = 0.64 (n-hexane/EtOAc, 3:1). 1H NMR
(400 MHz, CDCl3): δ = 1.52 (s, 9 H, CH3), 1.83–1.93 (m, 1 H, 3-H),
2.29–2.41 (m, 1 H, 3-H), 2.96–3.11 (m, 2 H, 4-H, 2-H), 3.48–3.52 (m,
1 H, 1-H), 4.25 (d, J = 4.8 Hz, 1 H, 5-H), 4.96–5.17 (m, 4 H, =CH),
5.73–5.87 (m, 2 H, =CH) ppm. 13C NMR (100 MHz, CDCl3): δ = 28.5,
37.7, 42.3, 45.0, 59.9, 63.3, 115.0, 116.2, 139.6, 141.1, 167.3,
168.5 ppm. MS (ESI): m/z = 286.00 [M + Na]+. C15H21NO3 (263.34):
calcd. C 68.42, H 8.04, N 5.32; found C 68.18, H 7.84, N 5.10.
Ethyl (1R*,2S*,3S*,5R*)-2-Amino-3-[(E)-3-ethoxy-3-oxoprop-1-
en-1-yl]-5-vinylcyclopentanecarboxylate Hydrochloride [(±)-5b]
White solid (120 mg, 89 %). M.p. 121–124 °C. Rf = 0.67 (CH2Cl2/
MeOH, 95:5). 1H NMR (400 MHz, [D6]DMSO): δ = 1.12–1.26 (m, 6 H,
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CH3), 1.40–1.55 (m, 1 H, 4-H), 2.04–2.17 (m, 1 H, 4-H), 2.87–3.05 (m,
3 H, 1-H, 3-H, 5-H), 3.60–3.72 (m, 1 H, 2-H), 4.02–4.21 (m, 4 H, OCH2),
4.92–5.13 (m, 2 H, =CH), 5.72–6.02 (m, 2 H, =CH), 6.86–7.00 (m, 1
H, =CH), 8.26 (br. s. 3 H, NH) ppm. 13C NMR (100 MHz, [D6]DMSO):
δ = 14.9, 15.1, 36.7, 46.7, 46.9, 51.2, 56.0, 60.8, 61.7, 116.5, 123.2,
139.9, 148.6, 166.5, 171.8 ppm. MS (ESI): m/z = 282.21 [M + H]+.
C15H24ClNO4 (317.81): calcd. C 56.69, H 7.61, N 4.41; found C 56.49,
H 7.44, N 4.14.
Ethyl (1R*,2S*,3S*,5R*)-2-Benzamido-3-[(E)-3-ethoxy-3-oxo-
prop-1-en-1-yl]-5-vinylcyclopentanecarboxylate [(±)-6b]
White solid (93 mg, 77 %). M.p. 107–110 °C. Rf = 0.52 (n-hexane/
EtOAc, 2:1). 1H NMR (400 MHz, CDCl3): δ = 1.17 (t, J = 8.0 Hz, 3 H,
CH3), 1.27 (t, J = 7.2 Hz, 3 H, CH3), 1.45–1.58 (m, 1 H, 4-H), 2.13–2.24
(m, 1 H, 4-H), 2.86–2.97 (m, 1 H, 3-H), 2.98–3.10 (m, 2 H, 1-H, 5-H),
4.00–4.23 (m, 4 H, OCH2), 4.61–4.73 (m, 1 H, 2-H), 5.00–5.15 (m 2
H, =CH), 5.75–5.96 (m, 2 H, =CH), 6.83 (d, J = 8.0 Hz, 1 H, NH), 6.88–
6.98 (m, 1 H, =CH), 7.37–7.46 (m, 2 H, Ar-H), 7.46–7.53 (m, 1 H, Ar-
H), 7.69–7.76 (m, 2 H, Ar-H) ppm. 13C NMR (100 MHz, CDCl3): δ =
14.5, 14.6, 36.8, 47.0, 49.2, 52.2, 55.7, 60.8, 61.5, 115.8, 122.9, 127.3,
129.0, 132.1, 139.7, 148.1, 166.5, 167.2, 174.5 ppm. MS (ESI): m/z =
386.25 [M + H]+. C22H27NO5 (385.46): calcd. C 68.55, H 7.06, N 3.63;
found C 68.22, H 6.88, N 3.12.
Ethyl (1R*,2S*,3S*,5R*)-2-Amino-3-[(E)-3-methoxy-3-oxoprop-1-
en-1-yl]-5-vinylcyclopentanecarboxylate Hydrochloride [(±)-5a]
White solid (80 mg, 58 %). M.p. 116–118 °C. Rf = 0.64 (CH2Cl2/MeOH,
95:5). 1H NMR (400 MHz, [D6]DMSO): δ = 1.20 (t, J = 7.1 Hz, 3 H,
CH3), 1.41–1.54 (m, 1 H, 4-H), 2.05–2.16 (m, 1 H, 4-H), 2.90–3.01 (m,
3 H, 1-H, 3-H, 5-H), 3.64–3.69 (m, 4 H, OCH3, 2-H), 4.05–4.20 (m, 2
H, OCH2), 4.99–5.11 (m, 2 H, =CH), 5.73–5.85 (m, 1 H, =CH), 5.98 (d,
J = 12.0 Hz, 1 H, =CH), 6.88–6.98 (m, 1 H, =CH), 8.21 (br s. 3 H, NH)
ppm. 13C NMR (100 MHz, [D6]DMSO): δ = 15.0, 36.6, 46.7, 46.9, 51.2,
52.3, 56.0, 61.7, 116.6, 122.9, 140.0, 148.8, 168.3, 171.9 ppm. MS
(ESI): m/z = 268.18 [M + H]+. C14H22ClNO4 (303.79): calcd. C 55.35,
H 7.30, N 4.61; found C 55.16, H 7.12, N 4.42.
Ethyl (1R*,2S*,3S*,5R*)-2-Benzamido-3-[(E)-3-methoxy-3-oxo-
prop-1-en-1-yl]-5-vinylcyclopentanecarboxylate [(±)-6a]
White solid (73 mg, 60 %). M.p. 137–141 °C. Rf = 0.49 (n-hexane/
EtOAc, 2:1). 1H NMR (400 MHz, CDCl3): δ = 1.17 (t, J = 7.2 Hz, 3 H,
CH3), 1.46–1.59 (m, 1 H, 4-H), 2.14–2.25 (m, 1 H, 4-H), 2.86–2.98 (m,
1 H, 3-H), 2.99–3.10 (m, 2 H, 1-H, 5-H), 3.70 (s, 3 H, OCH3), 4.02–4.18
(m, 2 H, OCH2), 4.62–4.73 (m, 1 H, 2-H), 5.02–5.15 (m, 2 H, =CH),
5.76–5.88 (m, 1 H, =CH), 5.93 (d, J = 16.40 Hz, 1 H, =CH), 6.86 (d,
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J = 9.6 Hz, 1 H, NH), 6.90–6.99 (m, 1 H, =CH), 7.39–7.45 (m, 2 H, Ar-
H), 7.46–7.52 (m, 1 H, Ar-H), 7.70–7.76 (m, 2 H, Ar-H) ppm. 13C NMR
(100 MHz, CDCl3): δ = 14.6, 36.8, 47.0, 49.3, 51.9, 52.2, 55.6, 61.5,
115.8, 122.5, 127.3, 129.0, 132.1, 139.6, 148.3, 166.9, 167.2,
174.5 ppm. MS (ESI): m/z = 372.28 [M + H]+. C21H25NO5 (371.43):
calcd. C 67.91, H 6.78, N 3.77; found C 67.68, H 6.60, N 3.50.
Ethyl (1S*,2S*,3S*,5R*)-2-Benzamido-3-[(E)-3-methoxy-3-oxo-
prop-1-en-1-yl]-5-vinylcyclopentanecarboxylate [(±)-16a]
White solid (56 mg, 47 %). M.p. 115–118 °C. Rf = 0.58 (n-hexane/
EtOAc, 1:1). 1H NMR (400 MHz, CDCl3): δ = 1.22 (t, J = 7.2 Hz, 3 H,
CH3), 1.66–1.80 (m, 1 H, 4-H), 2.00–2.14 (m, 1 H, 4-H), 3.02–3.22 (m,
2 H, 3-H, 5-H), 3.24–3.35 (m, 1 H, 1-H), 3.69 (s, 3 H, OCH3), 4.02–4.21
(m, 2 H, OCH2), 4.38–4.48 (m, 1 H, 2-H), 4.98–5.12 (m, 2 H, =CH),
5.66–5.78 (m, 1 H, =CH), 5.90 (d, J = 15.6 Hz, 1 H, =CH), 6.70 (d, J =
7.6 Hz, 1 H, N-H), 6.94–7.03 (m, 1 H, =CH), 7.33–7.41 (m, 2 H, Ar-H),
7.42–7.49 (m, 1 H, Ar-H), 7.72 (d, J = 7.5 Hz, 2 H, Ar-H) ppm. 13C
NMR (100 MHz, CDCl3): δ = 14.7, 36.7, 44.8, 47.3, 51.9, 53.9, 59.6,
61.0, 116.8, 122.3, 127.3, 128.9, 132.0, 137.5, 149.4, 167.1, 168.0,
173.4 ppm. MS (ESI): m/z = 372.22 [M + H]+. C21H25NO5 (371.43):
calcd. C 67.91, H 6.78, N 3.77; found C 67.70, H 6.64, N 3.54.
Ethyl (1S*,2S*,3S*,5R*)-2-Benzamido-3-[(E)-3-ethoxy-3-oxo-
prop-1-en-1-yl]-5-vinylcyclopentanecarboxylate (±)-16b
White solid (54 mg, 44 %). M.p. 145–147 °C. Rf = 0.68 (n-hexane/
EtOAc, 1:1). 1H NMR (400 MHz, CDCl3): δ = 1.16–1.39 (m, 6 H, CH3),
1.69–1.83 (m, 1 H, 4-H), 2.01–2.17 (m, 1 H, 4-H), 3.05–3.25 (m, 2 H,
3-H, 5-H), 3.29–3.38 (m, 1 H, 1-H), 4.07–4.23 (m, 4 H, OCH2), 4.32–
4.41 (m, 1 H, 2-H), 4.99–5.14 (m, 2 H, =CH), 5.66–5.80 (m, 1 H, =CH),
5.90 (d, J = 14.8 Hz, 1 H, =CH), 6.26 (d, J = 7.6 Hz, 1 H, NH), 6.92–
7.03 (m, 1 H, =CH), 7.37–7.45 (m, 2 H, Ar-H), 7.46–7.54 (m, 1 H, Ar-
H), 7.67–7.76 (m, 2 H, Ar-H) ppm. 13C NMR (100 MHz, CDCl3): δ =
14.6, 14.7, 36.8, 44.9, 47.1, 53.7, 59.8, 60.8, 61.1, 116.8, 122.9, 127.4,
129.0, 132.0, 137.5, 148.9, 166.6, 167.9, 173.4 ppm. MS (ESI): m/z =
386.28 [M + H]+. C22H27NO5 (385.46): calcd. C 68.55, H 7.06, N 3.63;
found C 68.38, H 6.84, N 3.34.
Ethyl (1S*,2S*,3S*,5R*)-2-Benzamido-3-[(E)-3-oxobut-1-en-1-yl]-
5-vinylcyclopentanecarboxylate [(±)-17]
Brown oil (57 mg, 50 %). Rf = 0.44 (n-hexane/EtOAc, 1:1). 1H NMR
(400 MHz, CDCl3): δ = 1.23 (t, J = 7.2 Hz, 3 H, CH3), 1.69–1.82 (m, 1
H, 4-H), 2.05–2.15 (m, 1 H, 4-H), 2.23 (s, 3 H, COCH3), 2.95–3.07 (m,
1 H, 3-H), 3.11–3.30 (m, 2 H, 1-H, 5-H), 4.05–4.23 (m, 2 H, OCH2),
4.47–4.59 (m, 1 H, 2-H), 4.99–5.14 (m, 2 H, =CH), 5.67–5.79 (m, 1
H, =CH), 6.1 (d, J = 16.8 Hz, 1 H, =CH), 6.62 (d, J = 7.2 Hz, 1 H, NH),
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6.78–6.88 (m, 1 H, =CH), 7.35–7.43 (m, 2 H, Ar-H), 7.44–7.51 (m, 1 H,
Ar-H), 7.72 (d, J = 7.5 Hz, 2 H, Ar-H) ppm. 13C NMR (100 MHz, CDCl3):
δ = 14.7, 27.3, 36.9, 44.9, 48.2, 54.1, 59.6, 61.1, 116.9, 127.4, 128.9,
132.0, 132.3, 137.4, 148.4, 168.0, 173.3, 199.1 ppm. MS (ESI): m/z =
356.36 [M + H]+. C21H25NO4 (355.43): calcd. C 70.96, H 7.09, N 3.94;
found C 70.81, H 6.83, N 3.66.
Ethyl (2R*,3R*,4R*,5S*)-4-Benzamido-5-[(E)-3-ethoxy-3-oxo-
prop-1-en-1-yl]-2-vinyltetrahydrofuran-3-carboxylate [(±)-27]
White solid (37 mg, 30 %). M.p. 156–162 °C. Rf = 0.40 (n-hexane/
EtOAc, 2:1). 1H NMR (400 MHz, CDCl3): δ = 1.13–1.37 (m, 6 H, CH3),
3.63–3.74 (m, 1 H, 3-H), 4.06–4.27 (m, 4 H, OCH2), 4.42–4.52 (m, 1
H, 4-H), 4.65–4.77 (m, 1 H, 5-H), 4.88–4.97 (m, 1 H, 2-H), 5.25 (d, J =
10.4 Hz, 1 H, =CH), 5.41 (d, J = 17.1 Hz, 1 H, =CH), 5.76–5.88 (m, 1
H, =CH), 6.09–6.18 (m, 1 H, =CH), 6.51 (d, J = 7.0 Hz, 1 H, NH), 7.06
(dd, J = 15.9, J = 5.5 Hz, 1 H, =CH), 7.38–7.46 (m, 2 H, Ar-H), 7.47–
7.56 (m, 1 H, Ar-H), 7.71–7.80 (m, 2 H, Ar-H) ppm. 13C NMR (100 MHz,
CDCl3): δ = 14.6, 54.0, 59.6, 61.0, 61.6, 80.4, 81.0, 118.9, 123.1, 127.4,
129.2, 132.4, 134.0, 144.5, 166.6, 168.1, 171.2 ppm. MS (ESI): m/z =
388.39 [M + H]+. C21H25NO6 (387.43): calcd. C 65.10, H 6.50, N 3.62;
found C 64.88, H 6.27, N 3.39.
X-ray Structure Determination: A crystal of (±)-16a was immersed
in cryo-oil, mounted in a MiTeGen loop, and measured at 100 K
with a Rigaku Oxford Diffraction Supernova diffractometer using
Mo-Kα (λ = 0.71073) radiation. The CrysAlisPro[12] program package
was used for cell refinement and data reduction. Multiscan absorp-
tion correction (CrysAlisPro) was applied to the intensities before
structure solution. The structure was solved by the charge-flipping
method using the SUPERFLIP[13] software. Structural refinements
were carried out using SHELXL-2014[14] with the SHELXLE[15] graphi-
cal user interface. Hydrogen atoms were positioned geometrically
and constrained to ride on their parent atoms with C–H 0.95–0.99 Å,
N–H 0.88 Å, and Uiso = 1.2–1.5·Ueq (parent atom). Crystallographic
Table 1. Crystal data.
(±)-16a
Empirical formula C21H25NO5
Formula mass 371.42
T [K] 100(2)
λ [Å] 0.71073
Crystal system monoclinic
Space group P21/c
a [Å] 12.8600(4)
b [Å] 16.2546(4)
c [Å] 9.6694(3)
 [°] 97.616(3)
V [Å3] 2003.40(10)
Z 4
ρcalcd. [Mg/m3] 1.231
μ(Kα) [mm–1] 0.088
No. of reflections 8937
Unique reflections 4938
GOOF (F2) 1.031
Rint 0.0312
R1[a] (I ≥ 2σ) 0.0570
wR2[b] (I ≥ 2σ) 0.1370
[a] R1 = Σ||Fo| – |Fc||/Σ |Fo|. [b] wR2 = {Σ[w(Fo2 – Fc2)2]/Σ [w(Fo2)2]}1/2.
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details are summarized in Table 1. CCDC 1524896 [for (±)-16a] con-
tains the supplementary crystallographic data for this paper. These
data can be obtained free of charge from The Cambridge Crystallo-
graphic Data Centre.
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